secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001193125-23-294328
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology to cut 12% of workforce, close R&D sites; charges $30-40M
---------------------------------------------------------------------------

- Workforce reduction of ~75 positions (12%) and closure of St. Louis and Portland R&D facilities in 2024.
- Estimated pre-tax charges of $30-40M, primarily facility-related; $3-4M cash expenditures. Annual savings at least $40M.
- Company to focus on chronic hepatitis delta/B programs and expand monoclonal antibody platform into autoimmune and oncology.
- Research to continue at San Francisco and Bellinzona sites.
- Cash, equivalents, and investments of $1.7B as of Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/0001193125-23-294328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/d643902d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-294328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer